Alike but not the same: Anatomic heterogeneity of estrogen receptor-mediated vasodilation

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 1, 2013, Pages 22-25

  Barton, Matthias ^a   Meyer, Matthias R ^a,b,c   Prossnitz, Eric R ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CAROTID ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HORMONAL THERAPY; HUMAN; HYPERPOLARIZATION; LUNG CIRCULATION; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PULMONARY ARTERY; REVIEW; VASCULAR SMOOTH MUSCLE; VASODILATATION;

CARDIOVASCULAR DISEASES; ESTROGENS; FEMALE; HUMANS; MALE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VASODILATION;

EID: 84880572564     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31829709d4     Document Type: Review

References (49)

1. Mügge A, Riedel M, Barton M, et al. Endothelium-independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc Res. 1993;27:1939-1942.
2. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986;320:134-139
3. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMPregulated gene transcription. Proc Natl Acad Sci U S A. 1994;91:8517-8521.
4. Szego CM, Davis JS. Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen. Proc Natl Acad Sci U S A. 1967;58:1711-1718.
5. Bittner V. Menopause and cardiovascular risk cause or consequence? J Am Coll Cardiol. 2006;47:1984-1986.
6. Rosano GM, Collins P, Gerbara O, et al. Effect of estradiol 17beta upon coronary artery vasoconstrictor response to methylergometrine maleate in female menopausal patients. Int J Cardiol. 2006;107:254-259.
7. MacKenzie JN. Irritation of the sexual apparatus. Am J Med Sci. 1884;87: 360
8. Reynolds SRM, Foster FL. Vascular action of estrogen in the human male. J Clin Invest. 1939;18:649-655.
9. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. Pharmacol Rev. 2008;60:210-241.
10. Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension. 2009;54:11-18.
11. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett. 1987;210:37-39.
12. Kim KH, Toomre D, Bender J.R. Splice isoform estrogen receptors as integral transmembrane proteins. Mol Biol Cell. 2011;22:4415-4423.
13. Kim KH, Moriarty K, Bender J.R. Vascular cell signaling by membrane estrogen receptors. Steroids. 2008;73:864-869.
14. Szego CM, Davis JS. Inhibition of estrogen-induced elevation of cyclic 3',5'-adenosine monophosphate in rat uterus. I. By beta-adrenergic receptor-blocking drugs. Mol Pharmacol. 1969;5:470-480.
15. Colburn P, Buonassisi V. Estrogen-binding sites in endothelial cell cultures. Science. 1978;201:817-819.
16. Buonassisi V, Venter JC. Hormone and neurotransmitter receptors in an established vascular endothelial cell line. Proc Natl Acad Sci U S A. 1976;73:1612-1616.
17. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288:373-376.
18. Furchgott RF. A research trail over half a century. Annu Rev Pharmacol Toxicol. 1995;35:1-27.
19. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, et al. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res. 1997;81:885-892.
20. Takada Y, Kato C, Kondo S, et al. Cloning of cDNAs encoding G proteincoupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem Biophys Res Commun. 1997;240:737-741.
21. Jensen EV, DeSombre ER. Estrogen-receptor interaction. Science. 1973; 182:126-134.
22. Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen-receptor interactions in target tissues. Arch Anat Microsc Morphol Exp. 1967;56:547-569.
23. Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011;7:715-726.
24. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996-2009.
25. Pedram A, Razandi M, O'Mahony F, et al. Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling. Sci Signal. 2013;6:ra36.
26. Meyer MR, Haas E, Prossnitz ER, et al. Non-genomic regulation of vascular cell function and growth by estrogen. Mol Cell Endocrinol. 2009;308:9-16.
27. Meyer MR, Prossnitz ER, Barton M. The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol. 2011;55:17-25.
28. Haas E, Meyer MR, Schurr U, et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension. 2007;49:1358-1363.
29. Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006;47:1019-1026.
30. Reslan OM, Yin Z, do Nascimento GR, et al. Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic and abdominal vasculature of female rat. J Cardiovasc Pharmacol. 2013;62:26-40.
31. Broughton BR, Miller AA, Sobey CG. Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am J Physiol Heart Circ Physiol. 2010;298:H1055-H1061.
32. Haas E, Bhattacharya I, Brailoiu E, et al. Regulatory role of G-protein coupled estrogen receptor for vascular function and obesity. Circ Res. 2009;104:288-291.
33. Lindsey SH, Cohen JA, Brosnihan KB, et al. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology. 2009;150:3753-3758.
34. Kurt AH, Buyukafsar K. Vasoconstriction induced by G1, a G-proteincoupled oestrogen receptor1 (GPER-1) agonist, in the isolated perfused rat kidney. Eur J Pharmacol. 2013;702:71-78.
35. Murata T, Dietrich HH, Xiang C, et al. G protein-coupled estrogen receptor agonist improves cerebral microvascular function after hypoxia/reoxygenation injury in male and female rats. Stroke. 2013;44: 779-785.
36. Blasko E, Haskell CA, Leung S, et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol. 2009;214:67-77.
37. Traupe T, Stettler CD, Li H, et al. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension. 2007;49:1364-1370.
38. Barton M. Position paper: the membrane estrogen receptor GPER clues and questions. Steroids. 2012;77:935-942.
39. Luksha L, Poston L, Gustafsson JA, et al. The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J Physiol. 2006;577:945-955.
40. Meyer MR, Haas E, Barton M. Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis. Gend Med. 2008;5:S19-S33.
41. Barton M. Cholesterol and atherosclerosis: modulation by estrogen. Curr Opin Lipidol. 2013;24:214-220.
42. Meyer MR, Barton M. ERalpha, ERbeta, and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis. Cardiovasc Res. 2009; 83:605-610.
43. Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2:207-212.
44. Dennis MK, Burai R, Ramesh C, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009;5:421-427.
45. Dennis MK, Field AS, Burai R, et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol. 2011;127:358-366.
46. Lappano R, Rosano C, De Marco P, et al. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol. 2011;320:162-170.
47. Vivacqua A, Bonofiglio D, Albanito L, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Mol Pharmacol. 2006; 70:1414-1423.
48. Rosano C, Lappano R, Santolla MF, et al. Recent advances in the rationale design of GPER ligands. Curr Med Chem. 2012;19:6199-6206.
49. Lappano R, Santolla MF, Pupo M, et al. MIBE acts as antagonist ligand of both estrogen receptor alpha and GPER in breast cancer cells. Breast Cancer Res. 2012;14:R12.